Home Page
Omnisense Offers Increased Accuracy in Fracture Risk Assessment
Dusseldorf, Germany, MEDICA (November 16, 1999) Sunlight OmnisenseTM, Sunlight Ultrasound Technologies' breakthrough device for the diagnosis of osteoporosis, increases the specificity of fracture risk assessment, according to a study released last week.

The study, presented at the annual meeting of the American College of Rheumatology in Boston, shows that changes in bone strength measurements vary at different skeletal sites. The researchers stated that single-site evaluation may sub-optimally estimate the skeletal involvement in osteoporosis.

The Sunlight OmnisenseTM is a one-of-a-kind ultrasound device that measures bone strength at multiple skeletal sites, enabling unprecedented accuracy and precision in the prediction of fracture risk. In addition, the device is compact, cost-effective, user- and patient- friendly and is easily installed in primary care facilities.

Osteoporosis is a global epidemic responsible for more than 1.5 million fractures annually. Eighty percent of those affected by osteoporosis are women. In fact, a womanís risk of hip fracture is equal to her combined risk of breast, uterine and ovarian cancer. An average of 24% of hip fracture patients aged 50 and older will die of complications in the year following their fracture. While osteoporosis is often thought of as an older personís disease, it can strike at any age. All of this adds up to great costs in quality of life and huge healthcare expenses.

Osteoporosis is a treatable disease, but early detection of bone loss is crucial to prevent fractures. With the help of the Sunlight OmnisenseTM, routine screening in the comfort and security of the patientís primary care doctor's office is now possible.